Developer docs
API playgroundTry for free, no card

Search company profiles

Vericel Corp

Full company profile

uuid0004gy6

Namestring
Vericel Corp
Legal namestring
Vericel Corporation
Websiteurl
vcel.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Vericel Corporation is a commercial-stage biotechnology company headquartered in Burlington, Massachusetts that develops, manufactures, and markets autologous cell therapies for the U.S. sports medicine and severe burn care markets. Its commercial portfolio consists of three core products: MACI (autologous cultured chondrocytes on a porcine collagen membrane) for repair of symptomatic full-thickness knee cartilage defects, including the MACI Arthro arthroscopic delivery variant; Epicel (cultured epidermal autografts) for permanent skin replacement in severe burns covering ≥30% of total body surface area; and NexoBrid (anacaulase-bcdb), a proteolytic enzyme product for enzymatic eschar removal in thermal burns, for which Vericel holds exclusive North American commercial rights under license from MediWound. The underlying platform relies on proprietary autologous cell expansion and tissue engineering processes performed in GMP-certified facilities, with a new Burlington manufacturing facility approved by FDA in March 2026 to support scaled production.

The company monetizes its products primarily through specialty pharmaceutical commercial sales to orthopedic surgeons (MACI) and burn care specialists (Epicel, NexoBrid), reimbursed through Medicare, Medicaid, and private insurance, alongside a ten-year BARDA procurement contract valued at up to $197 million for NexoBrid supply to the U.S. Strategic National Stockpile. Vericel employs an enterprise field sales model that it is actively expanding through 2025-2026 to support domestic growth and a planned 2027 international launch starting in the United Kingdom. The company is publicly traded on NASDAQ under VCEL and ended 2025 with approximately $276 million in revenue, $200 million in cash, no debt, and consecutive years of GAAP profitability, with 2026 revenue guided to $326-336 million.

Short descriptiontext

Vericel Corporation is a commercial-stage biotech that manufactures and markets autologous cell therapies — MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid for eschar removal — sold to orthopedic surgeons and burn care specialists in the United States.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
autologous cell therapy, cartilage repair products, burn care treatments, regenerative medicine, biological skin grafts
Industry3 codes
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1MACI Product Sales
TypeOne Time License
Description

Revenue from MACI cartilage repair product sales. MACI revenue was $56.4 million in Q1 2026 (22% growth) and $239.5 million in 2025 full year. Primary revenue driver representing approximately 87% of total revenue.

stocktitan.net
2Burn Care Products (Epicel + NexoBrid)
TypeOne Time License
Description

Revenue from Epicel skin grafts and NexoBrid eschar removal product. Burn Care revenue was $12.0 million in Q1 2026 (91% growth) and $36.5 million in 2025 full year.

stocktitan.net
3BARDA Government Contract
TypeManaged Services
Description

Ten-year BARDA contract valued at up to $197 million for procurement of NexoBrid for U.S. Strategic National Stockpile, vendor managed inventory setup, and development of next-generation formulations including blast trauma indication and room temperature stable formulation. Base period includes approximately $10 million over first 12 months.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MACI
Description

Autologous cultured chondrocytes on porcine collagen membrane for repair of symptomatic, full-thickness cartilage defects of the knee in adult patients.

vcel.com
+2 more records
Core offering1 text field

Vericel manufactures and markets advanced autologous cell therapy products for two specialty markets: sports medicine (MACI, autologous cultured chondrocytes on a porcine collagen membrane, plus the MACI Arthro arthroscopic delivery system for repair of symptomatic full-thickness knee cartilage defects up to 4 cm²) and severe burn care (Epicel, cultured epidermal autografts for permanent skin replacement in patients with deep dermal or full-thickness burns covering ≥30% of total body surface area, and NexoBrid, an FDA-approved botanical proteolytic enzyme product for enzymatic eschar removal in adult and pediatric thermal burn patients, held under exclusive North American commercial rights).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • MACI revenue growth of 22% to $56.4 million in Q1 2026
+4 more records
Product overview1 text field

Vericel Corporation is a biotechnology company that manufactures and markets advanced cell therapy products for sports medicine and severe burn care. The company's product portfolio consists of three core marketed products: MACI (autologous cultured chondrocytes on porcine collagen membrane) for cartilage repair in the knee, with its MACI Arthro sub-product enabling less invasive arthroscopic delivery; Epicel (cultured epidermal autograft) for permanent skin replacement in severe burn patients; and NexoBrid (anacaulase-bcdb) for eschar removal in thermal burns. Vericel also holds rights to the legacy product Carticel. The products leverage autologous cell therapy technology, growing patients' own cells to create personalized treatments.

Product and service5 records
1MACI
CategoryCell Therapy / Sports Medicine
Description

MACI (autologous cultured chondrocytes on porcine collagen membrane) is an FDA-approved autologous cellularized scaffold product for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. It is the first FDA-approved product that applies tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee, marketed to orthopedic surgeons and sports medicine specialists.

2MACI Arthro
CategoryCell Therapy / Sports Medicine
Description

MACI Arthro is an FDA-approved arthroscopic delivery system for MACI using custom-designed instrumentation, enabling repair of knee cartilage defects up to 4 cm² through small incisions and reducing surgical trauma and patient recovery time versus traditional open surgery.

3Epicel
CategoryCell Therapy / Burn Care
Description

Epicel (cultured epidermal autograft, CEA) is a permanent skin graft grown from a patient's own skin cells, indicated for deep dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. From two postage stamp-sized biopsies, Vericel can grow enough skin to cover the patient's entire body, marketed to burn centers and burn surgeons.

4NexoBrid
CategoryBurn Care / Specialty Pharmaceutical
Description

NexoBrid (anacaulase-bcdb) is a botanical drug product containing proteolytic enzymes indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel holds exclusive North American commercial rights, providing rapid enzymatic debridement in approximately four hours while selectively preserving viable tissue, marketed to burn centers and burn surgeons.

5Carticel
CategoryCell Therapy / Sports Medicine (Legacy)
Description

Carticel was the first autologous cell therapy for treatment of cartilage lesions in the knee, originally commercialized in Europe by Genzyme Tissue Repair. Vericel acquired global rights in 2014 and the product is referenced as a legacy offering in the company's current portfolio.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-04-03
Description

Vericel holds exclusive North American commercial rights to NexoBrid, a biological orphan product approved for eschar removal of severe thermal burns. MediWound announced Vericel was awarded a ten-year BARDA contract valued at up to $197 million for procurement and development of NexoBrid. The contract includes initial procurement for U.S. Strategic National Stockpile, development of next-generation formulations, and potential blast trauma indication.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Specialty surgical and regenerative medicine company with skin regeneration (Integra Dermal Regeneration Template) and wound care products overlapping with Vericel's Epicel franchise. Comparable in burn and skin substitute end markets.

TypeBroad incumbent
Description

Medical device company with sports medicine and orthopedic product lines, including biologic and regenerative offerings (e.g., via Biorez). Comparable in targeting orthopedic surgeons for cartilage and soft tissue procedures, with overlapping channel motion.

TypeBroad incumbent
Description

Global medical device company with a sports medicine and orthobiologics franchise (including cartilage repair and regenerative products) targeting the same orthopedic surgeons who use MACI. Comparable on customer base and channel, though Vericel is more concentrated in autologous cell therapy.

TypeDirect peer
Description

Regenerative medicine company marketing placental tissue allografts (e.g., EpiFix) for wound care and surgical applications. Comparable in product category (regenerative/biologic skin and wound care) and commercial motion targeting wound care specialists and surgeons.

TypeBroad incumbent
Description

Large diversified orthopedic and medical device company with sports medicine, orthobiologics, and regenerative offerings. Comparable due to shared orthopedic surgeon customer base and procedural overlap in cartilage-related sports medicine procedures.

TypeEmerging player
Description

Cell therapy company developing allogeneic cellular medicines for inflammatory and musculoskeletal conditions, including cartilage indications. Comparable in cell-therapy platform approach and orthopedic/regenerative targets, though still largely pre-commercial.

TypeDirect peer
Description

Commercial-stage regenerative medicine company focused on skin and wound healing products (e.g., Apligraf, Dermagraft) for advanced wound care. Closely comparable to Vericel's Epicel franchise in product type (skin substitutes) and end markets (severe/chronic wounds, burn care).

TypeDirect peer
Description

Developer and manufacturer of NexoBrid; Vericel's licensor and channel partner for the burn care franchise. Most directly comparable to Vericel's burn care business line, with overlapping technology (enzymatic eschar removal) and shared BARDA/government channel.

TypeEmerging player
Description

Specialty orthobiologics and regenerative medicine company with cartilage repair (e.g., hyaluronic acid viscosupplements) and emerging regenerative pipeline. Comparable in targeting sports medicine / orthopedic indications, though concentrated in HA-based rather than cell-based therapies.

TypeDirect peer
Description

Commercial-stage autologous cell therapy company (Provenge for prostate cancer). Comparable as a fellow commercial-stage autologous cell therapy manufacturer with similar manufacturing complexity, reimbursement dynamics, and direct-to-specialist sales model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vericel Corp

Cell Therapy Pharmaceuticalsvcel.com

Vericel Corporation is a commercial-stage biotech that manufactures and markets autologous cell therapies — MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid for eschar removal — sold to orthopedic surgeons and burn care specialists in the United States.

What Vericel Corp does

Vericel Corporation is a commercial-stage biotechnology company headquartered in Burlington, Massachusetts that develops, manufactures, and markets autologous cell therapies for the U.S. sports medicine and severe burn care markets. Its commercial portfolio consists of three core products: MACI (autologous cultured chondrocytes on a porcine collagen membrane) for repair of symptomatic full-thickness knee cartilage defects, including the MACI Arthro arthroscopic delivery variant; Epicel (cultured epidermal autografts) for permanent skin replacement in severe burns covering ≥30% of total body surface area; and NexoBrid (anacaulase-bcdb), a proteolytic enzyme product for enzymatic eschar removal in thermal burns, for which Vericel holds exclusive North American commercial rights under license from MediWound. The underlying platform relies on proprietary autologous cell expansion and tissue engineering processes performed in GMP-certified facilities, with a new Burlington manufacturing facility approved by FDA in March 2026 to support scaled production.

The company monetizes its products primarily through specialty pharmaceutical commercial sales to orthopedic surgeons (MACI) and burn care specialists (Epicel, NexoBrid), reimbursed through Medicare, Medicaid, and private insurance, alongside a ten-year BARDA procurement contract valued at up to $197 million for NexoBrid supply to the U.S. Strategic National Stockpile. Vericel employs an enterprise field sales model that it is actively expanding through 2025-2026 to support domestic growth and a planned 2027 international launch starting in the United Kingdom. The company is publicly traded on NASDAQ under VCEL and ended 2025 with approximately $276 million in revenue, $200 million in cash, no debt, and consecutive years of GAAP profitability, with 2026 revenue guided to $326-336 million.

Vericel Corp firmographics

Firmographics
Name
Vericel Corp
Legal name
Vericel Corporation
Website
https://vcel.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Vericel Corporation is a commercial-stage biotech that manufactures and markets autologous cell therapies — MACI for knee cartilage repair, Epicel for severe burns, and NexoBrid for eschar removal — sold to orthopedic surgeons and burn care specialists in the United States.
Ownership category
akta.pro rank

Vericel Corp industry classification

Industry
Product category
Cell Therapy Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Autologous cell therapy
  • Cartilage repair products
  • Burn care treatments
  • Regenerative medicine
  • Biological skin grafts

Where Vericel Corp is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Vericel Corp business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. MACI Product Sales: Revenue from MACI cartilage repair product sales. MACI revenue was $56.4 million in Q1 2026 (22% growth) and $239.5 million in 2025 full year. Primary revenue driver representing approximately 87% of total revenue.
  2. Burn Care Products (Epicel + NexoBrid): Revenue from Epicel skin grafts and NexoBrid eschar removal product. Burn Care revenue was $12.0 million in Q1 2026 (91% growth) and $36.5 million in 2025 full year.
  3. BARDA Government Contract: Ten-year BARDA contract valued at up to $197 million for procurement of NexoBrid for U.S. Strategic National Stockpile, vendor managed inventory setup, and development of next-generation formulations including blast trauma indication and room temperature stable formulation. Base period includes approximately $10 million over first 12 months.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Vericel Corp product offering

Product offering

Core offering

Vericel manufactures and markets advanced autologous cell therapy products for two specialty markets: sports medicine (MACI, autologous cultured chondrocytes on a porcine collagen membrane, plus the MACI Arthro arthroscopic delivery system for repair of symptomatic full-thickness knee cartilage defects up to 4 cm²) and severe burn care (Epicel, cultured epidermal autografts for permanent skin replacement in patients with deep dermal or full-thickness burns covering ≥30% of total body surface area, and NexoBrid, an FDA-approved botanical proteolytic enzyme product for enzymatic eschar removal in adult and pediatric thermal burn patients, held under exclusive North American commercial rights).

Product overview

Vericel Corporation is a biotechnology company that manufactures and markets advanced cell therapy products for sports medicine and severe burn care. The company's product portfolio consists of three core marketed products: MACI (autologous cultured chondrocytes on porcine collagen membrane) for cartilage repair in the knee, with its MACI Arthro sub-product enabling less invasive arthroscopic delivery; Epicel (cultured epidermal autograft) for permanent skin replacement in severe burn patients; and NexoBrid (anacaulase-bcdb) for eschar removal in thermal burns. Vericel also holds rights to the legacy product Carticel. The products leverage autologous cell therapy technology, growing patients' own cells to create personalized treatments.

Differentiator

Problem solved

Functional benefit

Brands

  • MACI: Autologous cultured chondrocytes on porcine collagen membrane for repair of symptomatic, full-thickness cartilage defects of the knee in adult patients.
  • Epicel
  • NexoBrid

Products and services

  • MACI MACI (autologous cultured chondrocytes on porcine collagen membrane) is an FDA-approved autologous cellularized scaffold product for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. It is the first FDA-approved product that applies tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee, marketed to orthopedic surgeons and sports medicine specialists.
  • MACI Arthro MACI Arthro is an FDA-approved arthroscopic delivery system for MACI using custom-designed instrumentation, enabling repair of knee cartilage defects up to 4 cm² through small incisions and reducing surgical trauma and patient recovery time versus traditional open surgery.
  • Epicel Epicel (cultured epidermal autograft, CEA) is a permanent skin graft grown from a patient's own skin cells, indicated for deep dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. From two postage stamp-sized biopsies, Vericel can grow enough skin to cover the patient's entire body, marketed to burn centers and burn surgeons.
  • NexoBrid NexoBrid (anacaulase-bcdb) is a botanical drug product containing proteolytic enzymes indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel holds exclusive North American commercial rights, providing rapid enzymatic debridement in approximately four hours while selectively preserving viable tissue, marketed to burn centers and burn surgeons.
  • Carticel Carticel was the first autologous cell therapy for treatment of cartilage lesions in the knee, originally commercialized in Europe by Genzyme Tissue Repair. Vericel acquired global rights in 2014 and the product is referenced as a legacy offering in the company's current portfolio.

Quantifiable outcome

  • MACI revenue growth of 22% to $56.4 million in Q1 2026
  • +4 more outcomes

Companies that use Vericel Corp

Customer profile

Segments3 records

Ideal customer profiles3 records

Vericel Corp technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vericel Corp partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • MediWound Ltd.coreChannel Partner/ Reseller/ Distributor · 3 April 2026Vericel holds exclusive North American commercial rights to NexoBrid, a biological orphan product approved for eschar removal of severe thermal burns. MediWound announced Vericel was awarded a ten-year BARDA contract valued at up to $197 million for procurement and development of NexoBrid. The contract includes initial procurement for U.S. Strategic National Stockpile, development of next-generation formulations, and potential blast trauma indication.

Scale indicators8 records

Recent moves9 records

Expansion highlights5 records

Vericel Corp competitors and assessment

Company assessment

Broad incumbents

  • Integra LifeSciences: Specialty surgical and regenerative medicine company with skin regeneration (Integra Dermal Regeneration Template) and wound care products overlapping with Vericel's Epicel franchise. Comparable in burn and skin substitute end markets.
  • Conmed Corporation: Medical device company with sports medicine and orthopedic product lines, including biologic and regenerative offerings (e.g., via Biorez). Comparable in targeting orthopedic surgeons for cartilage and soft tissue procedures, with overlapping channel motion.
  • Smith & Nephew: Global medical device company with a sports medicine and orthobiologics franchise (including cartilage repair and regenerative products) targeting the same orthopedic surgeons who use MACI. Comparable on customer base and channel, though Vericel is more concentrated in autologous cell therapy.
  • Stryker: Large diversified orthopedic and medical device company with sports medicine, orthobiologics, and regenerative offerings. Comparable due to shared orthopedic surgeon customer base and procedural overlap in cartilage-related sports medicine procedures.

Direct peers

  • MiMedx Group: Regenerative medicine company marketing placental tissue allografts (e.g., EpiFix) for wound care and surgical applications. Comparable in product category (regenerative/biologic skin and wound care) and commercial motion targeting wound care specialists and surgeons.
  • Organogenesis Holdings: Commercial-stage regenerative medicine company focused on skin and wound healing products (e.g., Apligraf, Dermagraft) for advanced wound care. Closely comparable to Vericel's Epicel franchise in product type (skin substitutes) and end markets (severe/chronic wounds, burn care).
  • MediWound Ltd. Developer and manufacturer of NexoBrid; Vericel's licensor and channel partner for the burn care franchise. Most directly comparable to Vericel's burn care business line, with overlapping technology (enzymatic eschar removal) and shared BARDA/government channel.
  • Dendreon Pharmaceuticals: Commercial-stage autologous cell therapy company (Provenge for prostate cancer). Comparable as a fellow commercial-stage autologous cell therapy manufacturer with similar manufacturing complexity, reimbursement dynamics, and direct-to-specialist sales model.

Emerging players

  • Mesoblast: Cell therapy company developing allogeneic cellular medicines for inflammatory and musculoskeletal conditions, including cartilage indications. Comparable in cell-therapy platform approach and orthopedic/regenerative targets, though still largely pre-commercial.
  • Anika Therapeutics: Specialty orthobiologics and regenerative medicine company with cartilage repair (e.g., hyaluronic acid viscosupplements) and emerging regenerative pipeline. Comparable in targeting sports medicine / orthopedic indications, though concentrated in HA-based rather than cell-based therapies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vericel Corp social profiles

Digital presence

Vericel Corp compliance and trust

Trust signal

Compliance2 records

Vericel Corp financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vericel Corp leadership team

Management profile

Number of profiles

Profiles18 records

Vericel Corp funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vericel Corp M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vericel Corp

What does Vericel Corp do?

Vericel manufactures and markets advanced autologous cell therapy products for two specialty markets: sports medicine (MACI, autologous cultured chondrocytes on a porcine collagen membrane, plus the MACI Arthro arthroscopic delivery system for repair of symptomatic full-thickness knee cartilage defects up to 4 cm²) and severe burn care (Epicel, cultured epidermal autografts for permanent skin replacement in patients with deep dermal or full-thickness burns covering ≥30% of total body surface area, and NexoBrid, an FDA-approved botanical proteolytic enzyme product for enzymatic eschar removal in adult and pediatric thermal burn patients, held under exclusive North American commercial rights).

Is Vericel Corp a public or private company?

Vericel Corp is a public company. It is classified as public and is currently operating.

When was Vericel Corp founded?

Vericel Corp was founded in 2014. It employs 501 to 1,000 people.

Where is Vericel Corp based?

Vericel Corp is headquartered in Cambridge, United States, in the North America region.

How does Vericel Corp make money?

Three revenue lines are on record. MACI Product Sales are the primary driver. The others are burn Care Products (Epicel + NexoBrid) and BARDA Government Contract.

Who are Vericel Corp's main competitors?

Broad incumbents on record are Integra LifeSciences, Conmed Corporation, Smith & Nephew and Stryker. Direct peers are MiMedx Group, Organogenesis Holdings, MediWound Ltd. and Dendreon Pharmaceuticals. Emerging players are Mesoblast and Anika Therapeutics.

Does Vericel Corp have an API?

No public API is recorded for Vericel Corp.

What industry is Vericel Corp in?

Vericel Corp's product category is Cell Therapy Pharmaceuticals. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanVericel to Present at Stephens Conference Nov. 18Vericel Corporation will present at the Stephens Annual Investment Conference on November 18, 2026, at 4:30 p.m. ET. The webcast will be available on the company's Investor Relations website. The presentation covers Vericel's advanced therapies for sports medicine and severe burn care.The future of tradingVericel Director Robert L. Zerbe Reports Sale of Common Shares Worth $115,760Vericel director Robert L. Zerbe sold 2,000 common shares at $57.88 each and exercised options for 2,000 shares at $13.05 each on November 9, 2026. His direct holdings totaled 32,995 shares after the transactions.American Banking and Market NewsStephens Forecasts Strong Price Appreciation for Vericel (NASDAQ:VCEL) StockStephens raised its price target on Vericel from $55 to $68, maintaining an overweight rating. The company reported Q2 EPS of $0.27, beating estimates, with revenue up 26.5% year-over-year. Analysts average a Buy rating with a $62 target.ChartmillVERICEL CORP (NASDAQ:VCEL): Affordable Growth With Peer-Relative ValuationVericel Corp is rated for affordable growth with strong growth and profitability but expensive absolute valuation. Its trailing P/E of 92.23 and forward P/E of 61.73 exceed S&P 500 averages, yet it trades cheaper than most biotech peers. The company expects earnings growth of 65.99% over the next years.Simply Wall StEarnings Beat: Vericel Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their ModelsVericel Corporation reported Q3 revenue of $85m, 9.5% above estimates, and EPS of $0.27, 370% above expectations. Analysts' 2027 revenue and EPS forecasts remain unchanged at $392.9m and $0.88, with a price target of $59.71. The company is expected to grow revenue 17% annually, slower than the industry's 22%.YahooVericel (VCEL) Jumped, What Is Behind The Move?Vericel reported Q3 revenue of $85.37 million and net income of $14.16 million, raising its 2026 revenue outlook. Shares rose 35.67% in a week and 34.07% in a month, with a year-to-date return of 53.38%. The company targets $500 million revenue and high 30% adjusted EBITDA margins by 2029.Seeking AlphaVericel Corporation (VCEL) Q3 2026 Earnings Call TranscriptVericel Corporation reported an outstanding third quarter in its Q3 2026 earnings call on November 5, 2026. CEO Nick Colangelo and CFO Joe Mara discussed the results, with forward-looking statements and non-GAAP measures included.TradingViewHC Wainwright & Co. maintains Vericel at Buy, raises price target to $75 from $72HC Wainwright & Co. maintained Vericel at Buy and raised its price target to $75 from $72, a 4.2% increase. The target implies an upside of 44.8% from the Nov 5 close of $51.78.MarketWatchVerical Shares Rise After Higher 3Q Profit, Guidance IncreaseVericel shares rose 12% to $50.84 after reporting Q3 revenue of $85.4 million and net income of $14.2 million, both beating estimates. The company raised its 2026 revenue guidance to $344–346 million from $330–340 million.YahooVericel (VCEL) Stock Looks Overvalued Given Its Earnings SupportVericel shares have returned 28.9% over three years, but the stock trades at a P/E of 96.2x, far above the biotech industry's 16.6x and peer average of 9.6x. Analysts' fair P/E is a warning flag, implying the current price may be overvalued relative to earnings.